Copyright Reports & Markets. All rights reserved.

Global Lung Cancer Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Lung Cancer Diagnostics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Lung Cancer Diagnostics by Type
    • 1.3.1 Overview: Global Lung Cancer Diagnostics Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Lung Cancer Diagnostics Consumption Value Market Share by Type in 2023
    • 1.3.3 Immunoassays
    • 1.3.4 Flow Cytometry
    • 1.3.5 Rapid Tests
    • 1.3.6 Molecular Assays
    • 1.3.7 Tissue Arrays
    • 1.3.8 Circulating Tumor Cells
    • 1.3.9 Pharmacodiagnostics
    • 1.3.10 Biomarkers
    • 1.3.11 Other
  • 1.4 Global Lung Cancer Diagnostics Market by Application
    • 1.4.1 Overview: Global Lung Cancer Diagnostics Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Industrial
    • 1.4.3 Healthcare
    • 1.4.4 Other
  • 1.5 Global Lung Cancer Diagnostics Market Size & Forecast
  • 1.6 Global Lung Cancer Diagnostics Market Size and Forecast by Region
    • 1.6.1 Global Lung Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Lung Cancer Diagnostics Market Size by Region, (2019-2030)
    • 1.6.3 North America Lung Cancer Diagnostics Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Lung Cancer Diagnostics Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Lung Cancer Diagnostics Market Size and Prospect (2019-2030)
    • 1.6.6 South America Lung Cancer Diagnostics Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Lung Cancer Diagnostics Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Roche Diagnostics
    • 2.1.1 Roche Diagnostics Details
    • 2.1.2 Roche Diagnostics Major Business
    • 2.1.3 Roche Diagnostics Lung Cancer Diagnostics Product and Solutions
    • 2.1.4 Roche Diagnostics Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Roche Diagnostics Recent Developments and Future Plans
  • 2.2 BioMérieux
    • 2.2.1 BioMérieux Details
    • 2.2.2 BioMérieux Major Business
    • 2.2.3 BioMérieux Lung Cancer Diagnostics Product and Solutions
    • 2.2.4 BioMérieux Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 BioMérieux Recent Developments and Future Plans
  • 2.3 Qiagen
    • 2.3.1 Qiagen Details
    • 2.3.2 Qiagen Major Business
    • 2.3.3 Qiagen Lung Cancer Diagnostics Product and Solutions
    • 2.3.4 Qiagen Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Qiagen Recent Developments and Future Plans
  • 2.4 Advpharma
    • 2.4.1 Advpharma Details
    • 2.4.2 Advpharma Major Business
    • 2.4.3 Advpharma Lung Cancer Diagnostics Product and Solutions
    • 2.4.4 Advpharma Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Advpharma Recent Developments and Future Plans
  • 2.5 AIT Austrian Institute of Technology
    • 2.5.1 AIT Austrian Institute of Technology Details
    • 2.5.2 AIT Austrian Institute of Technology Major Business
    • 2.5.3 AIT Austrian Institute of Technology Lung Cancer Diagnostics Product and Solutions
    • 2.5.4 AIT Austrian Institute of Technology Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 AIT Austrian Institute of Technology Recent Developments and Future Plans
  • 2.6 Courtagen Life Sciences
    • 2.6.1 Courtagen Life Sciences Details
    • 2.6.2 Courtagen Life Sciences Major Business
    • 2.6.3 Courtagen Life Sciences Lung Cancer Diagnostics Product and Solutions
    • 2.6.4 Courtagen Life Sciences Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Courtagen Life Sciences Recent Developments and Future Plans
  • 2.7 DiagnoCure
    • 2.7.1 DiagnoCure Details
    • 2.7.2 DiagnoCure Major Business
    • 2.7.3 DiagnoCure Lung Cancer Diagnostics Product and Solutions
    • 2.7.4 DiagnoCure Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 DiagnoCure Recent Developments and Future Plans
  • 2.8 BioMark Diagnostics
    • 2.8.1 BioMark Diagnostics Details
    • 2.8.2 BioMark Diagnostics Major Business
    • 2.8.3 BioMark Diagnostics Lung Cancer Diagnostics Product and Solutions
    • 2.8.4 BioMark Diagnostics Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 BioMark Diagnostics Recent Developments and Future Plans
  • 2.9 Mayo Clinic
    • 2.9.1 Mayo Clinic Details
    • 2.9.2 Mayo Clinic Major Business
    • 2.9.3 Mayo Clinic Lung Cancer Diagnostics Product and Solutions
    • 2.9.4 Mayo Clinic Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Mayo Clinic Recent Developments and Future Plans
  • 2.10 HalioDx SAS
    • 2.10.1 HalioDx SAS Details
    • 2.10.2 HalioDx SAS Major Business
    • 2.10.3 HalioDx SAS Lung Cancer Diagnostics Product and Solutions
    • 2.10.4 HalioDx SAS Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 HalioDx SAS Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Lung Cancer Diagnostics Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Lung Cancer Diagnostics by Company Revenue
    • 3.2.2 Top 3 Lung Cancer Diagnostics Players Market Share in 2023
    • 3.2.3 Top 6 Lung Cancer Diagnostics Players Market Share in 2023
  • 3.3 Lung Cancer Diagnostics Market: Overall Company Footprint Analysis
    • 3.3.1 Lung Cancer Diagnostics Market: Region Footprint
    • 3.3.2 Lung Cancer Diagnostics Market: Company Product Type Footprint
    • 3.3.3 Lung Cancer Diagnostics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Lung Cancer Diagnostics Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Lung Cancer Diagnostics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Lung Cancer Diagnostics Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Lung Cancer Diagnostics Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Lung Cancer Diagnostics Consumption Value by Type (2019-2030)
  • 6.2 North America Lung Cancer Diagnostics Consumption Value by Application (2019-2030)
  • 6.3 North America Lung Cancer Diagnostics Market Size by Country
    • 6.3.1 North America Lung Cancer Diagnostics Consumption Value by Country (2019-2030)
    • 6.3.2 United States Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Lung Cancer Diagnostics Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Lung Cancer Diagnostics Consumption Value by Type (2019-2030)
  • 7.2 Europe Lung Cancer Diagnostics Consumption Value by Application (2019-2030)
  • 7.3 Europe Lung Cancer Diagnostics Market Size by Country
    • 7.3.1 Europe Lung Cancer Diagnostics Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 7.3.3 France Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Lung Cancer Diagnostics Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Lung Cancer Diagnostics Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Lung Cancer Diagnostics Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Lung Cancer Diagnostics Market Size by Region
    • 8.3.1 Asia-Pacific Lung Cancer Diagnostics Consumption Value by Region (2019-2030)
    • 8.3.2 China Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 8.3.5 India Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Lung Cancer Diagnostics Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Lung Cancer Diagnostics Consumption Value by Type (2019-2030)
  • 9.2 South America Lung Cancer Diagnostics Consumption Value by Application (2019-2030)
  • 9.3 South America Lung Cancer Diagnostics Market Size by Country
    • 9.3.1 South America Lung Cancer Diagnostics Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Lung Cancer Diagnostics Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Lung Cancer Diagnostics Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Lung Cancer Diagnostics Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Lung Cancer Diagnostics Market Size by Country
    • 10.3.1 Middle East & Africa Lung Cancer Diagnostics Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Lung Cancer Diagnostics Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Lung Cancer Diagnostics Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Lung Cancer Diagnostics Market Drivers
  • 11.2 Lung Cancer Diagnostics Market Restraints
  • 11.3 Lung Cancer Diagnostics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Lung Cancer Diagnostics Industry Chain
  • 12.2 Lung Cancer Diagnostics Upstream Analysis
  • 12.3 Lung Cancer Diagnostics Midstream Analysis
  • 12.4 Lung Cancer Diagnostics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Lung Cancer Diagnostics market size was valued at USD 1938 million in 2023 and is forecast to a readjusted size of USD 2805.4 million by 2030 with a CAGR of 5.4% during review period.
    Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    The Global Info Research report includes an overview of the development of the Lung Cancer Diagnostics industry chain, the market status of Industrial (Immunoassays, Flow Cytometry), Healthcare (Immunoassays, Flow Cytometry), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Lung Cancer Diagnostics.
    Regionally, the report analyzes the Lung Cancer Diagnostics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Lung Cancer Diagnostics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
    Key Features:
    The report presents comprehensive understanding of the Lung Cancer Diagnostics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Lung Cancer Diagnostics industry.
    The report involves analyzing the market at a macro level:
    Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Immunoassays, Flow Cytometry).
    Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Lung Cancer Diagnostics market.
    Regional Analysis: The report involves examining the Lung Cancer Diagnostics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
    Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Lung Cancer Diagnostics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
    The report also involves a more granular approach to Lung Cancer Diagnostics:
    Company Analysis: Report covers individual Lung Cancer Diagnostics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
    Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Lung Cancer Diagnostics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Industrial, Healthcare).
    Technology Analysis: Report covers specific technologies relevant to Lung Cancer Diagnostics. It assesses the current state, advancements, and potential future developments in Lung Cancer Diagnostics areas.
    Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Lung Cancer Diagnostics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
    Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
    Market Segmentation
    Lung Cancer Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
    Market segment by Type
    Immunoassays
    Flow Cytometry
    Rapid Tests
    Molecular Assays
    Tissue Arrays
    Circulating Tumor Cells
    Pharmacodiagnostics
    Biomarkers
    Other
    Market segment by Application
    Industrial
    Healthcare
    Other
    Market segment by players, this report covers
    Roche Diagnostics
    BioMérieux
    Qiagen
    Advpharma
    AIT Austrian Institute of Technology
    Courtagen Life Sciences
    DiagnoCure
    BioMark Diagnostics
    Mayo Clinic
    HalioDx SAS
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Lung Cancer Diagnostics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Lung Cancer Diagnostics, with revenue, gross margin and global market share of Lung Cancer Diagnostics from 2019 to 2024.
    Chapter 3, the Lung Cancer Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Lung Cancer Diagnostics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
    Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Lung Cancer Diagnostics.
    Chapter 13, to describe Lung Cancer Diagnostics research findings and conclusion.

    Buy now